These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8547753)

  • 1. Comment: adjuvant therapy decisions in node-negative breast cancer.
    Anand A; Anand N; Anand A
    Ann Pharmacother; 1995 Sep; 29(9):940-1. PubMed ID: 8547753
    [No Abstract]   [Full Text] [Related]  

  • 2. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of node-negative breast cancer.
    Hall PD; Lesher BA; Hall RK
    Ann Pharmacother; 1995 Mar; 29(3):289-98. PubMed ID: 7606076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia.
    Sakata S; Cronk M
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):94-5. PubMed ID: 23718901
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials.
    Rajagopal S; Goodman PJ; Tannock IF
    J Clin Oncol; 1994 Jun; 12(6):1296-304. PubMed ID: 8201392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.
    Kilian R; Porzsolt F
    Breast; 2005 Dec; 14(6):636-42. PubMed ID: 16183288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and cost-effectiveness issues in breast cancer treatment.
    Hillner BE
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oncotype DX recurrence score in the management of breast cancer cases.
    Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ
    Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
    Sail KR; Franzini L; Lairson DR; Du XL
    Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow micrometastases and adjuvant treatment of breast cancer.
    Yu JJ; Brennan M; Christos P; Osborne MP; Hoda S; Simmons RM
    Breast J; 2004; 10(3):181-5. PubMed ID: 15125741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of axillary dissection in mammographically detected breast cancer.
    Jamali FR; Kurtzman SH; Deckers PJ
    Surg Oncol Clin N Am; 1997 Apr; 6(2):343-58. PubMed ID: 9115500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.